377 results on '"Lucianò, Roberta"'
Search Results
52. MP28-16 GENERALIZABILITY OF THE MK-6482-004 TRIAL TO REAL-WORLD VHL PATIENTS: RESULTS FROM A PROSPECTIVE SURVEILLANCE STUDY
53. PD36-04 UTILITY OF PRE- AND POST-PEMBROLIZUMAB VESICAL IMAGING – REPORTING AND DATA SYSTEM (VIRADS) TO PREDICT THE PATHOLOGICAL RESPONSE IN MUSCLE-INVASIVE UROTHELIAL BLADDER CANCER (MIBC): AN ANALYSIS OF THE PURE-01 COHORT
54. The Learning Curve for Radical Nephrectomy for Kidney Cancer: Implications for Surgical Training
55. Correction to: Renal histology across the stages of chronic kidney disease
56. Human Prostate Tissue-derived Extracellular Matrix as a Model of Prostate Microenvironment
57. Utility of pre- and post-pembrolizumab (Pembro) Vesical Imaging–Reporting and Data System (VIRADS) to predict the pathological response in muscle-invasive urothelial bladder cancer (MIBC): An analysis of the PURE-01 cohort.
58. Early increase in circulating carbonic anhydrase IX: A potential new predictive biomarker of preeclampsia
59. Case of the Month from San Raffaele Hospital, Milan, Italy: paraneoplastic presentation of small renal masses
60. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
61. PD37-07 THULIUM FIBER VS THULIUM YAG LASER EFFECT ON UPPER URINARY TRACT SOFT TISSUE: AN EX VIVO STUDY
62. PD40-10 FORMAL VALIDATION AT FINAL PATHOLOGY AFTER RADICAL NEHRECTOMY OF NEPHROMETRY SCORES: DISCORDANCE RATES AND OVERTREATMENT RISK
63. MP56-02 NEOADJUVANT PEMBROLIZUMAB MAY RESULT IN LONG-TERM OUTCOME IMPROVEMENT IN BIOMARKER-UNSELECTED PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER (MIBC): UPDATED RESULTS FROM PURE-01
64. MP50-03 SYSTEMATIC DEFINITION OF TREATMENT MODALITY AND CLINICAL OUTCOMES REPORTING SYSTEM IN CASE OF SURGICAL TREATMENT FOR VON HIPPEL-LINDAU RENAL CELL CARCINOMA
65. MP27-02 NOT ALL ADVERSE PATHOLOGY FEATURES ARE EQUAL: IDENTIFYING OPTIMAL CANDIDATES FOR ADJUVANT RADIOTHERAPY AMONG PATIENTS WITH ADVERSE PATHOLOGY AT RADICAL PROSTATECTOMY
66. PD60-03 THE IMPACT OF HISTOLOGICAL VARIANTS ON THE PERFORMANCE CHARACTERISTICS OF 68GA-PSMA PET/CT IN THE PRIMARY AND RECURRENT SETTING
67. MP47-09 THE ADDED VALUE OF HISTOLOGICAL SUBTYPE IN THE PREDICTION OF ONCOLOGIC OUTCOMES IN PATIENTS WITH NON-METASTATIC PAPILLARY RENAL CELL CARCINOMA
68. MP53-07 HISTOLOGICAL VARIANTS OF PROSTATE CANCER ARE UNDER-REPORTED IN PROSTATE BIOPSIES ASSESSED OUTSIDE TERTIARY REFERRAL CENTERS. A PLEA FOR BIOPSY REVIEW FOR OPTIMAL PATIENT MANAGEMENT
69. MP40-19 HOW TO IDENTIFY PATIENTS SUITABLE FOR CONSERVATIVE MANAGEMENT OF UPPER TRACT UROTHELIAL CARCINOMA (UTUC) ACCORDING TO TUMOR SIZE: IMPLICATIONS FOR CLINICAL GUIDELINES
70. An open-label, phase 2 study of personalized approach with perioperative immunotherapy for bladder preservation in muscle-invasive urothelial bladder carcinoma (MIBC).
71. Molecular characterization to delineate the clonal evolution of primary prostate cancer with synchronous lymph node metastasis.
72. A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02
73. Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study
74. A mechanistic insight into the anti-metastatic role of the prostate specific antigen
75. Leiomyoadenomatoid tumours of the epididymis: A new case report and review of the literature
76. Dissecting patterns of care in patients with variant histology of bladder cancer and lymph node invasion
77. PD42-05 FECAL MICROBIOTA PROFILING OF PATIENTS TREATED WITH NEOADJUVANT PEMBROLIZUMAB FOR MUSCLE INVASIVE UROTHELIAL CARCINOMA
78. MP83-08 THIRTY YEARS OF RADICAL PROSTATECTOMIES AT A SINGLE TERTIARY CARE REFERRAL CENTER
79. Multiparametric magnetic resonance imaging of the prostate underestimates tumour volume of small visible lesions
80. Sex-specific Alterations in the Urinary and Tissue Microbiome in Therapy-naïve Urothelial Bladder Cancer Patients
81. LONG TERM OUTCOMES OF SALVAGE LYMPH NODE DISSECTION FOR CLINICALLY RECURRENT PROSTATE CANCER: RESULTS OF A SINGLE INSTITUTION SERIES WITH A MINIMUM FOLLOW-UP OF 5 YEARS: MP70-15
82. IMPACT OF SURGICAL VOLUME ON SURGICAL MARGIN STATUS IN PATIENTS TREATED WITH ROBOT-ASSISTED RADICAL PROSTATECTOMY: MP37-02
83. Stool microbiota profiling of patients with muscle invasive bladder cancer receiving neoadjuvant pembrolizumab.
84. Conservative treatment of upper urinary tract carcinoma in patients with imperative indications
85. Prostate cancer testicular metastasis: Are they underestimated? Case report and analysis of the literature
86. Thulium:YAG Versus Holmium:YAG Laser Effect on Upper Urinary Tract Soft Tissue: Evidence from an Ex Vivo Experimental Study
87. Case of the Month from San Raffaele Hospital, Milan, Italy: paraneoplastic presentation of small renal masses.
88. PD-L1 Expression and CD8+ T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer
89. Assessment of HER2 Protein Overexpression and Gene Amplification in Renal Collecting Duct Carcinoma: Therapeutic Implication
90. Pre-clinical Research on Bladder Toxicity After Radiotherapy for Pelvic Cancers: State-of-the Art and Challenges
91. Abstract PR07: Development of a biomarker-based nomogram to predict the pathologic response to neoadjuvant pembrolizumab in muscle-invasive urothelial bladder cancer (MIBC)
92. The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial
93. Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer
94. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer
95. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study
96. Abstract A33: Intratissutal and urinary microbiome in therapy-naive bladder cancer patients: Definition of a gender-specific common microbiome
97. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies
98. MP55-20 INCONGRUENCE BETWEEN TURB AND RADICAL CYSTECTOMY FINDINGS IN TERMS OF HISTOLOGICAL VARIANT IDENTIFICATION: ANALYSIS OF ALL POTENTIAL CLINICAL RISK FACTORS
99. MP55-19 IMPACT OF HISTOLOGICAL VARIANTS IN NODE POSITIVE PATIENTS TREATED WITH RADICAL CYSTECTOMY FOR BLADDER CANCER
100. Multiparametric magnetic resonance imaging of the prostate underestimates tumour volume of small visible lesions.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.